Tumour-cell apoptosis after cisplatin treatment is not telomere dependent

International Journal of Cancer

Volumn 118, Issue 11, 2006, Pages 2727-2734

  Jeyapalan, Jessie C ^a,b   Saretzki, Gabriele ^a   Leake, Alan ^a   Tilby, Michael J ^b   Von Zglinicki, Thomas ^a,c  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

Apoptosis; Cisplatin; DNA damage; Neuroblastoma; Telomerase; Telomeres

Indexed keywords

CISPLATIN; HISTONE H2AX; TELOMERASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CROSS LINKING; CYTOTOXICITY; DNA DAMAGE; DNA STRAND BREAKAGE; ENZYME ACTIVITY; GROWTH DISORDER; HELA CELL; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; PRIORITY JOURNAL; TELOMERE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CISPLATIN; DNA DAMAGE; HELA CELLS; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; NEUROBLASTOMA; SIGNAL TRANSDUCTION; TELOMERE;

EID: 33646360827     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21675     Document Type: Article

References (47)

1. Henkels KM, Turchi JJ. Induction of apoptosis in cisplatin-sensitive and -resistant human ovarian cancer cell lines. Cancer Res 1997;57:4488-92.
2. Ormerod MG, O'Neill C, Robertson D, Kelland LR, Harrap KR. cis-diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 1996;37:463-71.
3. Pinto AL, Lippard SJ. Binding of the antitumor drug cis- diamminedichloroplatinum(II) (cisplatin) to DNA. Biochim Biophys Acta 1985;780.
4. Kelland LR. New platinum antitumor complexes. Crit Rev Oncol Hematol 1993;15:191-219.
5. Knox RJ, Friedlos F, Lydall DA, Roberts JJ. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res 1986;46:1972-9.
6. von Zglinicki T. Oxidative stress shortens telomeres. Trends Biochem Sci 2002;27(7):339-44.
7. Grimaldi KA, McAdam SR, Souhami RL, Hartley JA. DNA damage by anti-cancer agents resolved at the nucleotide level of a single copy gene: evidence for a novel binding site for cisplatin in cells. Nucleic Acids Res 1994;22(12):2311-17.
8. Griffith JD, Comeau L, Rosenfield S, Stansel RM, Bianchi A, Moss H, de Lange T. Mammalian telomeres end in a large duplex loop. Cell 1999;97:503-14.
9. Saretzki G, Sitte N, Merkel U, Wurm RE, von Zglinicki T. Telomere shortening triggers a p53-dependent cell cycle arrest via accumulation of G-rich single stranded DNA fragments. Oncogene 1999;18:5148-58.
10. Stewart SA, Ben-Porath I, Carey VJ, O'Connor BF, Hahn WC, Weinberg RA. Erosion of the telomeric single-strand overhang at replicative senescence. Nat Genet 2003;33(4):492-6.
11. von Zglinicki T. Telomeres and replicative senescence: is it only length that counts? Cancer Lett 2001;168(2):111-16.
12. Greider CW, Blackburn EH. The telomere terminal transferase of Tetrahymena is a ribonucleoprotein enzyme with two kinds of primer specificity. Cell 1987;51:887-98.
13. Greider C, Blackburn EH. A telomeric sequence in the RNA of Tetrahymenatelomerase required for telomere repeat synthesis. Nature 1989;337:331-7.
14. Hiyama E, Hiyama K, Yokoyama T, Matsuura Y, Piatyszek MA, Shay JW. Correlating telomerase activity levels with human neuroblastoma outcomes. Nature Med 1995;1:249-55.
15. Brinksmidt C, Poremba C, Christiansen H, Simon R, Schafer KL, Tepe HJ, Lampert F, Boecker W, Dcockhorn-Dworniczak B. Comparative genomic hybridization and telomerase activity analysis identify two biologically different groups of four neuroblastomas. British J Cancer 1998;77:2223-9.
16. Burger AM, Double JA, Newell DR. Inhibition of telomerase activity by cisplatin in human testicular cancer cells. Europ J Cancer 1997;33:638-44.
17. Zhang RG, Zhang RP, Wang XW, Xie H. Effects of cisplatin on telomerase activity and telomere length in BEL-7404 human hepatoma cells. Cell Res 2002;12(1):55-62.
18. Kunifuji Y, Gotoh S, Abe T, Miura M, Karasaki Y. Down regulation of telomerase activity by anticancer drugs in human ovarian cancer cells. Anti-Cancer Drugs 2002;13:595-8.
19. Ishibashi K, Wakasugi S, Ogawa K, Kato H, Endo S, Yoshimatsu K, Haga S, Hirose K, Kajiwara T. [Detection of telomerase activity in intestinal lavage solution from colorectal carcinoma patients]. Nippon Rinsho 1998;56(5):1209-13.
20. Kondo Y, Kondo S, Tanaka Y, Haqqi T, Barna BP, Cowell JK. Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis. Oncogene 1998;16(17):2243-8.
21. Kondo Y, Komata T, Kondo S. Combination therapy of 2-5A antisense against telomerase RNA and cisplatin for malignant gliomas. Int J Oncology 2001;18:1287-92.
22. Murakami J, Nagai N, Shigemasa K, Ohama K. Inhibition of telomerase activity and cell proliferation by a reverse transcriptase inhibitor in gynaecological cancer cell lines. Europ J Cancer 1999;35:1027-34.
23. Cressey TR, Tilby MJ, Newell DR. Decreased telomerase activity is not a reliable indicator of chemosensitivity in testicular cancer cell lines. Europ J Cancer 2002;38:586-93.
24. Akiyama M, Horiguchi-Yamada J, Saito S, Hoshi Y. Yamada O, Mizoguchi H, Yamada H. Cytostatic concentrations of anticancer agents do not affect telomerase activity of leukaemic cells in vitro. Europ J Cancer 1999;35:309-15.
25. Ludwig A, Saretzki G, Holm PS, Tiemann F, Lorenz M, Emrich T, Harley CB, von Zglinicki T. Ribozyme cleavage of telomerase mRNA sensitizes breast epithelial cells to inhibitors of topoisomerase. Cancer Res 2001;61(7):3053-61.
26. Ciccarone V, Spengler BA, Meyers MB, Biedler JL, Ross RA. Phenotypic diversification in human neuroblastoma cells: expression of distinct neural crest lineages. Cancer Res 1989;49:219-25.
27. Sgonc R, Gruber J. Apoptosis Detection: an overview. Exl Gerontol 1998;33(6):525-33.
28. Brabeck C, Pfeiffer R, Leake A, Beneke S, Meyer R, Burkle A. L-selegiline potentiates the cellular poly(ADP-ribosyl)ation response to ionizing radiation. J Pharmacol Exp Ther 2003;306:973-9.
29. von Zglinicki T, Pilger R, Sitte N. Accumulation of single-strand breaks is the major cause of telomere shortening in human fibroblasts. Free Radic Biol Med 2000;28(1):64-74.
30. Wright WE, Tesmer VM, Huffman KE, Levene SD, Shay JW. Normal human chromosomes have long G-rich telomeric overhangs at one end. Genes Dev 1997;11(21):2801-9.
31. Shilo Y. ATM and related protein kinases: safeguarding genomic integrity. Nature Rev Cancer 2003;3:155-68.
32. Huffman KE, Levene SD, Tesmer VM, Shay JW, Wright WE. Telomere shortening is proportional to the size of the G-rich telomeric overhang. J Biol Chem 2000;275:19719-22.
33. Ishibashi T, Lippard SJ. Telomere loss in cells treated with cisplatin. Proc Natl Acad Sci USA 1998;95:4219-23.
34. Takai H, Smogorzewska A, de Lange T. DNA damage foci at dysfunctional telomeres. Curr Biol 2003;13:1549-56.
35. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, Saretzki G, Carter NP, Jackson SP. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003;426(6963):194-8.
36. Herbig U, Jobling WA, Chen BP, Chen DJ, Sedivy JM. Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a). Mol Cell 2004;14(4):501-13.
37. Kruk PA, Rampino NJ, Bohr VA. DNA damage and repair in telomeres: relation to aging. Proc Natl Acad Sci USA 1995;92:258-62.
38. von Zglinicki T, Saretzki G, Docke W, Lotze C. Mild hyperoxia shortens telomeres and inhibits proliferation of fibroblasts: a model for senescence? Exp Cell Res 1995;220(1):186-93.
39. Yoon HJ, Choi IY, Kang MR, Kim SS, Muller MT, Spitzner JR, Chung IK. DNA topoisomerases II cleavage of telomeres in vitro and in vivo. Biochim Biophys Acta 1998;1395:110-20.
40. Lee K, Rudolph L, Ju Y, Greenberg RA, Cannizzaro L, Chin L, Weiler SR, DePinho RA. Telomere dysfunction alters the chemotherapeutic profile of transformed cells. Proc Natl Acad Sci USA 2001;98:3381-6.
41. Misawa M, Tauchi T, Sashida G, Nakajima A, Abe K, Ohyashiki JH, Ohyashiki K. Inhibition of human telomerase enhances the effect of chemotherapeutic agents in lung cancer cells. Int J Oncol 2002;21:1087-92.
42. Jeyapalan J, Leake A, Ahmed S, Saretzki G, Tilby M, von Zglinicki T. The role of telomeres in etoposide induced tumour cell death. Cell Cycle 2004;13(3):1169-76.
43. Ishii K, Yang WL, Cvijic ME, Kikuchi Y, Nagata I, Chin KV. Telomere shortening by cisplatin in yeast nucleotide excision repair mutant. Exp Cell Res 2000;255:95-101.
44. Kuranaga N, Shinomiya N, Mochizuki H. Long term cultivation of colorectal carcinoma cells with anticancer drugs induces drug resistance and telomere elongation: an in vito study. Biomed Central Cancer 2001;1:10.
45. Akeshima R, Kigawa J, Takahashi M, Oishi T, Kanamori Y, Itamochi H, Shimada M, Kamazawa S, Sato S, Terakawa N. Telomerase activity and p53-dependent apoptosis in ovarian cancer cells. British J Cancer 2001;84:1551-55.
46. Ku WC, Cheng AJ, Wang TC. Inhibition of telomerase activity by PKC inhibitors in human nasoparyngeal cancer cells in culture. Biochem Biophys Res Commun 1997;241:730-6.
47. Lin Z, Lim S, Viani MA, Sapp M, Lim MS. Down regulation of telomerase activity in malignant lymphomas by radiation and chemotherapeutic agents. Am J Pathol 2001;159:711-19.